Inhaled heparin in cystic fibrosis

European Respiratory Journal

Volumn 27, Issue 2, 2006, Pages 354-358

  Serisier, David J ^a,b   Shute, J K ^c   Hockey, P M ^b   Higgins, B ^c   Conway, J ^b   Carroll, M P ^b  

^a MATER ADULT HOSPITAL   (Australia)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Cystic fibrosis; Heparin; Inflammation; Mucolytic; Neutrophil elastase

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; HEPARIN; LEUKOCYTE ELASTASE; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DISEASE MARKER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; IN VIVO STUDY; LUNG FIBROSIS; MUCOLYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADULT; ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HUMANS; MALE; SPIROMETRY; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 31844439570     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00069005     Document Type: Article

References (32)

1. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantification of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999; 160: 186-191.
2. Bonfield TR, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-2118.
3. Dean TP, Dai Y, Shute JK, Church MK, Warner JO. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res 1993; 34: 159-161.
4. Meyer KC, Lewandoski JR, Zimmerman JJ, Nunley D, Calhoun WJ, Dopico GA. Human neutrophil elastase and elastase/alpha1-antiprotease complex in cystic fibrosis. Am Rev Respir Dis 1991; 144: 580-585.
5. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-854.
6. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995; 126: 515-523.
7. Pantin CF, Stead RJ, Hodson ME, Batten JC. Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis. Thorax 1986; 41: 34-38.
8. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212-216.
9. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637-642.
10. Paul K, Rietschel E, Ballmann M, et al. Bronchoalveolar lavage for the evaluation of anti-inflammatory treatment study group. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004; 169: 719-725.
11. Davies J, Trindade MT, Wallis C, Rosenthal M, Crawford O, Bush A. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 1997; 23: 243-248.
12. Ledson M, Gallagher M, Hart CA, Walshaw M. Nebulised heparin in Burkholderia cepacia colonised adult cystic fibrosis patients. Eur Respir J 2001; 17: 36-38.
13. Youngchaiyud P, Kettel L, Cugell DW. The effect of heparin aerosols on airway conductance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1969; 99: 449-452.
14. King M, Rubin BK. Pharmacologic approaches to discovery and development of new mucolytic agents. Adv Drug Deliv Rev 2002; 54: 1475-1490.
15. Tyrrell DJ, Horne AP, Holme KR, Preuss JMH, Page CP. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46: 151-208.
16. Matzner Y, Marx G, Drexler R, Eldor A. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 1984; 52: 134-137.
17. Volpi N. Inhibition of human leukocyte elastase activity by heparins: influence of charge density. Biochim Biophys Acta 1996; 1290: 299-307.
18. Ramdin L, Perks B, Sheron N, Shute JK. Regulation of interleukin-8 binding and function by heparin and alpha2-macroglobulin. Clin Exp Allergy 1998; 28: 616-624.
19. Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992; 84: 1478-1484.
20. Schuster A, Ueki I, Nadel JA. Neutrophil elastase stimulates tracheal submucosal gland secretion that is inhibited by ICI 200,355. Am J Physiol 1992; 262: L86-L91.
21. Amitani R, Wilson R, Rutman A, et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol 1991; 4: 26-32.
22. +-transport. Am J Physiol Lung Cell Mol Physiol 2005; 288: L813-L819.
23. Shute JK, Forsyth C, Hockey PM, Carroll MP. Anti-inflammatory effects of nebulised heparin in cystic fibrosis [abstract]. Am J Respir Crit Care Med 2000; 161: A75.
24. Bendstrup KE, Gram J, Jensen JI. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur Respir J 2002; 19: 606-610.
25. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolised recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148: 145-151.
26. American Thoracic Society. Standardization of spirometry - 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
27. Singh SJ, Morgan MD, Hardman AE, Rowe C, Bardsley PA. Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation. Eur Respir J 1994; 7: 2016-2020.
28. Quittner AL, Sweeny S, Watrous M, et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol 2000; 25: 403-414.
29. Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am J Respir Crit Care Med 2002; 166: 352-355.
30. Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 1993; 147: 160-163.
31. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993; 329: 90-95.
32. Salva PS, Doyle NA, Graham L, Eigen H, Doerschuck CM. TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients. Pediatr Pulmonol 1996; 21: 11-19.